Joanna Perry MNZM has been appointed to the Board of Helius Therapeutics - New Zealand’s largest licenced medicinal cannabis company.
The Chartered Accountant Fellow joins as an Independent Director and will Chair the Board’s Audit Finance Committee.
The appointment of Perry comes as the 100 percent New Zealand-owned private company prepares to enter both domestic and international markets.
“Joanna’s significant governance experience, combined with her well-known inquisitive probing, will be a real asset. Her nature to challenge and always seek continuous improvement strongly aligns with Helius’ internal cultural value of staying curious,” said Carmen Doran, Chief Executive of Helius Therapeutics.
Perry currently holds other senior independent directorships. As with many previous governance roles, she often leads responsibility for audit and risk. She has held many regulatory, advisory, standards and reporting-related roles, and was a long-time member of the former Crown entity, Securities Commission of New Zealand.
The Cambridge University graduate was awarded a Member New Zealand Order of Merit (MNZM) for Services to Accounting.
Having raised $48m in capital since 2018, Helius has invested significantly in both its facility and talent. The arrival of Perry to the Board of Helius is timely, with its state-of-the-art, integrated medicines manufacturing facility in Auckland’s East Tamaki set to power up.
“Our world-class executive leadership team is complete, and our board is equally excited to bring high quality, highly efficacious medicinal cannabis products to market with an exciting R&D pipeline to follow,” said Doran.
Joanna Perry says it is a once-in-a-lifetime opportunity to be involved with such an innovative biotechnology company, leading the infancy of New Zealand’s medicinal cannabis sector.
“I’m delighted to add my governance and financial experience to the vast pharmaceutical and cannabinoid medicine experience of the Helius team. It’s an incredible journey not only for Helius but for the country,” said Perry.
Perry has previously worked with the company’s cornerstone shareholder and Chairman, Guy Haddleton, and is looking forward to working with him again.
“I respect Guy’s steadfast commitment to business innovation globally. I also admire his personal passion to deliver safe and effective medicinal cannabis here in New Zealand to improve patients’ quality of life. He has built the team to get the job done,” said Perry.
